Who is the Representative Director and CEO of Senno Therapeutics Inc.?

The Representative Director and CEO of Senno Therapeutics is Chieko Mori.

On whose research results was Senno Therapeutics established?

Senno Therapeutics was established based on the research results of Professor Hideki Taniguchi at The University of Tokyo.

What is the main objective of the lead pipeline SEN-001 developed by the company?

The lead pipeline SEN-001 aims to complement and restore lost liver function for severe liver diseases like acute-on-chronic liver failure.

How much cumulative funding has Senno Therapeutics raised, and how will it be used?

Senno Therapeutics has raised a cumulative amount of 750 million yen, which will be used to propel non-clinical development and prepare for clinical trials.

Which project by the Japan Agency for Medical Research and Development has the company been selected for?

The company has been selected for the Drug Discovery Venture Ecosystem Enhancement Project by the Japan Agency for Medical Research and Development.

AI News NQ Analysis

Senno Therapeutics Accelerates Development of Cell Therapy Using iPS Cell-Derived Hepatoblasts

NQ Score 0/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Senno Therapeutics, aiming to resolve unmet medical needs in liver failure, raised funds totaling 750 million yen to accelerate the development of 'SEN-001', a cell therapy using allogeneic iPS cell-derived hepatoblasts.

AI Analysis

Frequently Asked Questions

Q: Who is the Representative Director and CEO of Senno Therapeutics Inc.?: A: The Representative Director and CEO of Senno Therapeutics is Chieko Mori.
Q: On whose research results was Senno Therapeutics established?: A: Senno Therapeutics was established based on the research results of Professor Hideki Taniguchi at The University of Tokyo.
Q: What is the main objective of the lead pipeline SEN-001 developed by the company?: A: The lead pipeline SEN-001 aims to complement and restore lost liver function for severe liver diseases like acute-on-chronic liver failure.
Q: How much cumulative funding has Senno Therapeutics raised, and how will it be used?: A: Senno Therapeutics has raised a cumulative amount of 750 million yen, which will be used to propel non-clinical development and prepare for clinical trials.
Q: Which project by the Japan Agency for Medical Research and Development has the company been selected for?: A: The company has been selected for the Drug Discovery Venture Ecosystem Enhancement Project by the Japan Agency for Medical Research and Development.